Whole cohort (n = 886; 1893 visits) | SSc with features of overlap disease (n = 221;628 visits) | SSc without features of overlap disease (n = 665; 1265 visits) | ||||
---|---|---|---|---|---|---|
Parameter | Odds ratio (95 % CI) | p Value | Odds ratio (95 % CI) | p Value | Odds ratio (95 % CI) | p Value |
Self-reported worsening of cardiopulmonary, vascular or skin symptomsa | 1.05 (0.57–1.94) | 0.87 | 1.24 (0.48–3.18) | 0.66 | 1.03 (0.45–2.35) | 0.94 |
Digital ulcers/necrosisa | 1.15 (0.84–1.56) | 0.38 | 1.62 (1.04–2.51) | 0.034 | 0.82 (0.53–1.27) | 0.37 |
Sclerodermaa | 0.97 (0.76–1.23) | 0.78 | 1.08 (0.75–1.58) | 0.67 | 0.87 (0.63–1.18) | 0.37 |
Tendon friction rubsa | 1.15 (0.64–2.08) | 0.64 | 2.31 (1.05–5.10 | 0.037 | 0.54 (0.19–1.53) | 0.24 |
Synovitis/arthritisa | 0.95 (0.69–1.31) | 0.76 | 1.18 (0.73–1.91) | 0.50 | 0.80 (0.51–1.25) | 0.32 |
Modified Rodnan skin score >14a | 0.98 (0.96–0.99) | 0.013 | 0.97 (0.95–1.01) | 0.087 | 0.98 (0.96–1.01) | 0.16 |
Erythrocyte sedimentation rate >30 mm/ha | 0.98 (0.98–0.99) | 0.022 | 0.99 (0.99–1.01) | 0.97 | 0.99 (0.97–0.99) | 0.026 |
DLCO <80 % predicteda | 0.81 (0.61–1.09) | 0.17 | 1.14 (0.66–1.96) | 0.65 | 0.72 (0.51–1.03) | 0.073 |
C-reactive protein >8 mg/La | 1.01 (0.99–1.01) | 0.90 | 0.97 (0.93–1.01) | 0.073 | 1.01 (0.99–1.01) | 0.41 |
BMIb | 0.91 (0.88–0.94) | <0.0005 | 0.90 (0.85–0.95) | <0.0005 | 0.91 (0.87–0.95) | <0.0005 |
FVC <80 % predictedb | 1.24 (0.78–1.97) | 0.37 | 2.90 (1.32–6.38) | 0.0080 | 0.87 (0.47–1.61) | 0.65 |